Long-term Immunogenicity and Efficacy of a Reduced Dose of Plasma-based Hepatitis B Vaccine in Young Adults

Overview

Journal Bull World Health Organ

Specialty Public Health

Date 1995 Jan 1

PMID 7554025

Citations 3

Authors

K T Goh

C J Oon

B H Heng

G K Lim

Affiliations

Soon will be listed here.

Abstract

A cohort of seronegative preclinical medical and dental students and another cohort of seronegative national service recruits who were immunized intramuscularly with a reduced dose (10 micrograms) of plasma-based hepatitis B vaccine (Merck, Sharp & Dohme) at the start of the study and at 1 month and 6 months thereafter were followed up for 5 years and 6 years, respectively. Among the medical and dental students, antibody to hepatitis B surface antigen (anti-HBs) ( > or = 10 mlU/ml) was detected in 81% of the vaccinees at the end of the 5-year follow-up and the geometric mean titre (GMT) had dropped from 412.6 mlU/ml one year after completion of vaccination to 174.9 mlU/ml after 5 years. Antibody to hepatitis B core antigen (anti-HBc) was detected in 0.4-1.0% of the vaccinees but none was positive for hepatitis B surface antigen (HBsAg) during the follow-up period. Among the national servicemen, the anti-HBs seroconversion rate and GMT were considerably lower than those of the preclinical medical and dental students. At the end of the 6-year follow-up, 55% of the vaccinees were positive for anti-HBs ( > or = 10 mlU/ml) and the GMT had dropped from 80.7 mlU/ml one year after completion of vaccination to 30.4 mlU/ml after 6 years. Anti-HBc was detected in 8 (2.7%) and transient HBs antigenaemia in 2 (0.7%) of 293 vaccinees after 4 years.(ABSTRACT TRUNCATED AT 250 WORDS)

Citing Articles

Booster dose vaccination for preventing hepatitis B.

Poorolajal J, Hooshmand E Cochrane Database Syst Rev. 2016; (6):CD008256.

PMID: 27271960 PMC: 7154826. DOI: 10.1002/14651858.CD008256.pub3.

Update on diagnosis, management, and prevention of hepatitis B virus infection.

Mahoney F Clin Microbiol Rev. 1999; 12(2):351-66.

PMID: 10194463 PMC: 88921. DOI: 10.1128/CMR.12.2.351.

Reduced doses of hepatitis B vaccines: is it a good idea?.

Kane M Bull World Health Organ. 1995; 73(4):529-30.

PMID: 7554026 PMC: 2486788.

References

Papaevangelou G, Vissoulis C, Richardson S, Krugman S . Immunogenicity of a five-microgram dose of hepatitis B vaccine. J Med Virol. 1985; 15(1):65-9. DOI: 10.1002/jmv.1890150109. View

MATSANIOTIS N, Kattamis C, Dionyssopouolou E, Laskari S . Immunogenicity of low doses of hepatitis B vaccine in normal children. Vaccine. 1985; 3(3):297-9. DOI: 10.1016/s0264-410x(85)90098-2. View

Hadler S, Francis D, MAYNARD J, THOMPSON S, Judson F, Echenberg D . Long-term immunogenicity and efficacy of hepatitis B vaccine in homosexual men. N Engl J Med. 1986; 315(4):209-14. DOI: 10.1056/NEJM198607243150401. View

Davidson M, Krugman S . Recombinant yeast hepatitis B vaccine compared with plasma-derived vaccine: immunogenicity and effect of a booster dose. J Infect. 1986; 13 Suppl A:31-8. DOI: 10.1016/s0163-4453(86)92653-8. View

Coursaget P, Yvonnet B, Chotard J, Sarr M, Vincelot P, Ndoye R . Seven-year study of hepatitis B vaccine efficacy in infants from an endemic area (Senegal). Lancet. 1986; 2(8516):1143-5. DOI: 10.1016/s0140-6736(86)90543-x. View

Oon C, Tan K, Goh K, Viegas O, McCarthy T, Chan S . Evaluation of a low dose of hepatitis B vaccine given within a childhood immunisation programme in Singapore. J Infect. 1986; 13(3):255-67. DOI: 10.1016/s0163-4453(86)91223-5. View

Moyes C, Milne A, Dimitrakakis M, Goldwater P, Pearce N . Very-low-dose hepatitis B vaccine in newborn infants: an economic option for control in endemic areas. Lancet. 1987; 1(8523):29-31. DOI: 10.1016/s0140-6736(87)90712-4. View

Milne A, Moyes C, Allwood G, Pearce N, Krugman S . Antibody responses to recombinant, yeast-derived hepatitis B vaccine in teenage New Zealand children. N Z Med J. 1988; 101(840):67-9. View

Ljunggren K, Lofgren B, Nordenfelt E . Varying antibody response in hospital staff vaccinated against hepatitis B. Scand J Infect Dis. 1988; 20(5):485-8. DOI: 10.3109/00365548809032495. View

10.

Goh K, Doraisingham S, Tan K, Oon C, Ho M, Chen A . The hepatitis B immunization programme in Singapore. Bull World Health Organ. 1989; 67(1):65-70. PMC: 2491227. View

11.

Goh K, Chan Y, Wong L, Kong K, Oon C, Guan R . The prevalence of hepatitis B virus markers in dental personnel in Singapore. Trans R Soc Trop Med Hyg. 1988; 82(6):908-10. DOI: 10.1016/0035-9203(88)90038-7. View

12.

Guan R, Tay H, Yap I, Smith R, Tan L . Immunogenicity of a low dose recombinant DNA hepatitis B vaccine in healthy adults in Singapore. Asian Pac J Allergy Immunol. 1989; 7(2):85-8. View

13.

Guan R, Tay H, Yap I, Smith R, Tan L . The immune response of low dose recombinant DNA hepatitis B vaccine in teenagers in Singapore. Trans R Soc Trop Med Hyg. 1990; 84(5):731-2. DOI: 10.1016/0035-9203(90)90167-d. View

14.

Kane M . Reduced doses of hepatitis B vaccines: is it a good idea?. Bull World Health Organ. 1995; 73(4):529-30. PMC: 2486788. View

15.

Deinhardt F . Aspects of vaccination against hepatitis B; passive-active immunization schedules and vaccination responses in different age groups. Scand J Infect Dis Suppl. 1983; 38:17-23. View

16.

Papaevangelou G, Vissoulis C, Stathopoulou P, Kolaitis N, Krugman S . Safety and immunogenicity of a further reduced dose (10 mcg) of the hepatitis B vaccine. Dev Biol Stand. 1983; 54:209-15. View

17.

Papaevangelou G, Vissoulis C, Stathopoulou P, Kolaitis N, Krugman S . Reduction of the dose of hepatitis B vaccine. J Infect. 1983; 7 Suppl 1:69-70. DOI: 10.1016/s0163-4453(83)96718-x. View

18.

Ayoola E . The immune response of healthy Nigerian adults to small doses of hepatitis B vaccine: comparison of 10- and 20-micrograms doses. J Med Virol. 1984; 13(3):223-5. DOI: 10.1002/jmv.1890130304. View

19.

Lelie P, Reesink H, Dees P, REERINK-BRONGERS E . Immunogenicity and safety of a plasma-derived heat-inactivated hepatitis B vaccine (CLB). Studies in volunteers at a low risk of infection with hepatitis B virus. Am J Epidemiol. 1984; 120(5):694-702. DOI: 10.1093/oxfordjournals.aje.a113936. View

20.

Goudeau A, Dubois F, Dubois M, Louq C, Mazert M . Immunogenicity of low dose (1.25 and 0.31 micrograms) hepatitis B vaccine. Lancet. 1984; 2(8411):1091-2. DOI: 10.1016/s0140-6736(84)91524-1. View